Who are Dual antithrombotc therapy-1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rosuvastatin plus clopidogrel, Dual antiplatelet agent duration, OAC + clopicogrel, Ticagrelor plus aspirin, Dabigatran + Ticagrelor, Dabigatran + clopidogrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dual-antithrombotc-therapy-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dual antithrombotc therapy-1 — Competitive Intelligence Brief

Dual antithrombotc therapy-1 (Dual antithrombotc therapy-1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent combination. Area: Cardiovascular.

marketed Antiplatelet agent combination Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Dual antithrombotc therapy-1 (Dual antithrombotc therapy-1) — The First Affiliated Hospital with Nanjing Medical University. Dual antiplatelet therapy combines two agents that work through different pathways to inhibit platelet aggregation and reduce thrombotic events.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dual antithrombotc therapy-1 TARGET	Dual antithrombotc therapy-1	The First Affiliated Hospital with Nanjing Medical University	marketed	Antiplatelet agent combination
Rosuvastatin plus clopidogrel	Rosuvastatin plus clopidogrel	Federal University of São Paulo	marketed	Statin plus antiplatelet agent combination	HMG-CoA reductase; P2Y12 receptor
Dual antiplatelet agent duration	Dual antiplatelet agent duration	Seoul National University Hospital	marketed	Antiplatelet agent combination	Cyclooxygenase (COX) and P2Y12 receptor
OAC + clopicogrel	OAC + clopicogrel	St. Antonius Hospital	marketed	Anticoagulant + antiplatelet agent combination	Coagulation cascade (OAC) and P2Y12 receptor (clopidogrel)
Ticagrelor plus aspirin	Ticagrelor plus aspirin	Fujian Medical University	marketed	Dual antiplatelet agent combination	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)
Dabigatran + Ticagrelor	Dabigatran + Ticagrelor	Zuyderland Medisch Centrum	marketed	Anticoagulant + antiplatelet agent combination	Thrombin (Factor IIa) and P2Y12 receptor
Dabigatran + clopidogrel	Dabigatran + clopidogrel	Zuyderland Medisch Centrum	marketed	Anticoagulant + antiplatelet agent combination	Thrombin (Factor IIa) and P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent combination class)

Beijing Tiantan Hospital · 1 drug in this class
Biosensors Europe SA · 1 drug in this class
Inova Health Care Services · 1 drug in this class
Kyunghee University Medical Center · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
University Hospital, Bordeaux · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dual antithrombotc therapy-1 — Competitive Intelligence Brief. https://druglandscape.com/ci/dual-antithrombotc-therapy-1. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab